BIOGEN INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 201.2 USD | -0.62% |
|
+6.27% | -21.76% |
| Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
| Apr. 25 | Goldman Sachs Adjusts Biogen Price Target to $340 From $393 | MT |
Presenter SpeechPaul Matteis (Analysts)Great. Thank you very much, everybody. It's my pleasure...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
202.5
USD
Average target price
286.5
USD
Spread / Average Target
+41.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.76% | 29.48B | |
| -4.66% | 87.53B | |
| +2.63% | 40.42B | |
| +56.65% | 25.43B | |
| -18.49% | 11.49B | |
| -44.02% | 11.3B | |
| -15.61% | 11.1B | |
| +4.04% | 8.75B | |
| -8.42% | 7.99B | |
| +0.71% | 7.67B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Transcript : Biogen Inc. Presents at Stifel CNS Days, Mar-28-2022 10
